APTEVO THERAPEUTICS INC. — Income Charts
11 years of history · ending 2022-12-31 · SEC EDGAR
Source:10-K · 10-Q
Revenue, Gross Profit, Operating Income & Net Income
Margin (%)
Operating Expenses
Income Breakdown
Revenue↓-86.5% -$20M
$3M
Cost of Revenue
$20M
R&D↓-49.5% -$18M
$18M
SG&A
$25M
D&A↓-62.3% -$1M
$901K
Operating Income↑+44.6% +$23M
$-29M
EBITDA↑+43.7% +$22M
$-28M
Other Income/Expense↑+1861.6% +$38M
$36M
Pretax Income↑+113.1% +$61M
$7M
Tax Provision
$-23M
Net Income↑+115.0% +$62M
$8M
Operating Margin↓-695.8pts
-919.7%
Net Margin↑+490.5pts
257.8%
Effective Tax Rate
41.7%
Deferred Tax Assets
$1M
Deferred Tax Liabilities
$2K
DTA Valuation Allowance↑+62.0% +$19M
$49M
Tax Credit Carryforwards
$3M
NOL Carryforwards↑+61.9% +$13M
$33M
ETR (Continuing Operations)↑+0.0pts
0.0%
ETR Federal Statutory↑+0.0pts
21.0%
ETR State + Local (pp)↓-4.3pts
-1.8%
ETR Foreign Differential (pp)
—
Operating Lease Cost↑+6.4% +$77K
$1M
Revenue YoY Variation↓-132.0pts
-74.7%
Income YoY Variation↓-38.1pts
-33.8%